Oral administration of Lactiplantibacillus plantarum 6.2 mitigates acute lung injury via immunostaining of the TLR4/NF-κB pathway and reduction of IL-17 in lung tissue.

backgroundAcute lung injury (ALI) is an inflammatory condition that compromises the lungs and is associated with substantial morbidity and mortality. In the absence of effective therapeutic options, the search for alternative treatments, such as probiotics, has intensified.

objectiveThis study investigated the anti-inflammatory potential of Lactiplantibacillus plantarum 6.2 (Lp62), administered orally in a murine ALI model. MATERIALS AND

methodsThirty male Swiss mice (N = 30) were randomly assigned to five groups (n = 6): negative control, healthy supplemented with Lp62 (Lp62), ALI, ALI supplemented with Lp62 (ALI+Lp62), and ALI treated with Dexamethasone (Dexa). Lp62 (10⁹ CFU/mL) was administered daily by oral gavage for one week. ALI was induced by intranasal instillation of LPS under anesthesia. Lungs were collected 24 h later for macroscopic examination. Histological evaluation used hematoxylin-eosin staining, and immunohistochemistry included anti-TLR4, anti-NF-κB, and anti-IL-17 antibodies. Total protein in bronchoalveolar lavage fluid (BALF) was measured by the Biuret method, and IL-1β by ELISA. Data were analyzed by one-way ANOVA with Tukey's post hoc test (p < 0.05).

resultsLp62 reduced cell migration, protein exudation, and IL-1β release in BALF, as well as macroscopic lung lesions, and attenuated histological inflammatory infiltration, increasing alveolar spaces. It also decreased TLR4, NF-κB, and IL-17 activation.

conclusionLactiplantibacillus plantarum 6.2 is a promising therapeutic approach for ALI by inhibiting the TLR4/NF-κB pathway and reducing neutrophil recruitment via IL-17-mediated signaling in mice.